{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075272","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.847076+00:00","generated_at":"2026-05-17T13:57:51.619337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2","bullets":["Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.","Net loss $6.0M for Q2 2025 vs. income $4.5M in Q2 2024, driven by warrant fair value change.","BX211 Phase 2: >40% wound size reduction vs placebo in diabetic foot osteomyelitis; registrational study planning underway.","BX004 Phase 2b in CF successfully initiated dosing; topline results expected Q1 2026.","Nature Comm. publication: BX004 showed ~500-fold (2.7 log₁₀) bacterial reduction vs placebo with no resistance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075272","json":"https://secwatch.observer/filing/0001213900-25-075272.json","markdown":"https://secwatch.observer/filing/0001213900-25-075272.md","text":"https://secwatch.observer/filing/0001213900-25-075272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/0001213900-25-075272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/ea0253022-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:51.619337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}